NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Short Interest Update

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 51,900 shares, a drop of 16.2% from the March 31st total of 61,900 shares. Approximately 2.6% of the shares of the company are sold short. Based on an average trading volume of 1,290,000 shares, the short-interest ratio is currently 0.0 days.

NeuroBo Pharmaceuticals Stock Up 2.6 %

Shares of NeuroBo Pharmaceuticals stock opened at $3.14 on Friday. The stock’s fifty day moving average is $4.43 and its 200 day moving average is $3.97. NeuroBo Pharmaceuticals has a one year low of $2.89 and a one year high of $6.75.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.